Portal de Periódicos da CAPES

Drug treatment for nasal allergy

1989; Wiley; Volume: 19; Issue: 5 Linguagem: Norueguês

10.1111/j.1365-2222.1989.tb02436.x

1365-2222

R.J. Davies, S. Ollier, Diana R. Cundell,

Food Allergy and Anaphylaxis Research

Clinical & Experimental AllergyVolume 19, Issue 5 p. 559-568 Drug treatment for nasal allergy R. J. Davies, R. J. Davies Department of Respiratory Medicine, St Bartholomew's Hospital, West Smithfield, London EC1A 7BESearch for more papers by this authorSusan Ollier, Susan Ollier Department of Respiratory Medicine, St Bartholomew's Hospital, West Smithfield, London EC1A 7BESearch for more papers by this authorDiana R. Cundell, Diana R. Cundell Department of Respiratory Medicine, St Bartholomew's Hospital, West Smithfield, London EC1A 7BESearch for more papers by this author R. J. Davies, R. J. Davies Department of Respiratory Medicine, St Bartholomew's Hospital, West Smithfield, London EC1A 7BESearch for more papers by this authorSusan Ollier, Susan Ollier Department of Respiratory Medicine, St Bartholomew's Hospital, West Smithfield, London EC1A 7BESearch for more papers by this authorDiana R. Cundell, Diana R. Cundell Department of Respiratory Medicine, St Bartholomew's Hospital, West Smithfield, London EC1A 7BESearch for more papers by this author First published: September 1989 https://doi.org/10.1111/j.1365-2222.1989.tb02436.xCitations: 8AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Fleming DM, Crombie DL. Prevalence of asthma and hay fever in England and Wales. Br Med J 1987; 294: 279–83. 2 Secher, C, Kirkegaard J, Borum P. Significance of H1 and H2 receptors in the human nose: rationale for topical use of combined antihistamine preparations. J Allergy Clin Immunol 1982; 70: 211–18. 3 Gomez E, Corrado O, Baldwin DL, Swanston AR, Davies RJ. Direct in vivo evidence for mast cell degranulation during allergen induced reactions in man. J Allergy Clin Immunol 1986; 778: 637–45. 4 Viegas M, Gomez E, Brooks J, Davies RJ. The effect of the pollen season on nasal mast cell numbers. Br Med J 1987; 294: 414. 5 Enerback L, Pipkorn U, Granerus G. Intra epithelial migration of nasal mucosal mast cells in hay fever. Int Arch Allergy Appl Immunol 1986; 80: 44–51. 6 Gomez E, Corrado OJ, Davies RJ. Histochemical and functional characteristics of the human nasal mast cell. Int Arch Allergy Appl Immunol 1987; 83: 52–6. 7 Irani AA, Schechter NM, Craig SS, de Blois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U.S.A. 1986; 83: 4464–8. 8 Wells E, Jackson CG, Harper ST, Mann J, Eady RP. Characterisation of primate broncho alveolar mast cells. II Inhibition of histamine, LTC4 and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells. J Immunol 1986; 137: 3941–5. 9 Togias A, Naclerio RM, Proud D, Baumgarten C, Peters S, Creticos PS, et al. Mediator release during nasal provocation. Am J Med 1985; 79(suppl 6a): 26–73. 10 Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NF, Meyers DA, Norman PS, Lichtenstein LM. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128: 597–602. 11 Davies RJ, Devalia JL. Histamine levels in nasal secretions: effect of methacholine and allergen. In: N Mygind, U Pipkorn, eds. Allergic and vasomotor rhinitis—pathophysiological aspects. Copenhagen : Munksgaard, 1977: 179–88. 12 Bisgaard H, Romeling F, Mygind N, Robinson C, Holgate ST, Church MK. In: N Mygind, U Pipkorn, eds. Allergic and vasomotor rhinitis—pathophysiological aspects. Copenhagen : Munksgaard, 1977: 189–97. 13 Naclerio RM, Okuda M, Pipkorn U. Late phase allergic reactions in the nose. In: Mygind N. Pipkorn U, eds. Allergic and vasomotor rhinitis—pathophysiological aspects. Copenhagen: Munksgaard, 1977: 165–71. 14 Naclerio RM, Proud D, Togias A, Adkinson NF, Meyers D, Kagey-Sobotka A, Plaur M, Lichtenstein LM. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313: 65–70. 15 Mullarkey MF, Hill JS, Webb DR, Allergic and non-allergic rhinitis: their characterisation with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 1980; 65: 122–6. 16 Pipkorn U, Karlsson G, Enerback L. The cellular response of the human allergic mucosa to natural allergen exposure. J Allergy Clin Immunol 1988; 81: 172. 17 Capron M, Capron A. The IgE receptor of human eosinophils. In: AB Kay, ed. Allergy and inflammation. London : Academic Press. 1987: 151–9. 18 Gleich GJ, Frigas E, Filley WV, Loegering DA. Eosinophils and bronchial inflammation. In: AB Kay, KF Austen, LM Lichtenstein, eds. Asthma: physiology, immunopharmacology and treatment. London : Academic Press, 1984: 195–208. 19 Cuss FM, Dixon CMS, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet 1986; i: 189–92. 20 Pipkorn U, Karlsson G, Bake B. Effect of platelet activating factor on the human nasal mucosa. Allergy 1984; 39: 141–5. 21 Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16: 289–97. 22 Mackay JA, Cromwell O, Kay AB. Allergen induced release of high molecular weight neutrophil chemotactic activity in nasal secretions from patients with allergic rhinitis. Thorax 1985; 40: 719. 23 Shaw RJ, Fitzharris P, Cromwell O, Wardlaw AJ, Kay AB. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy 1985; 40: 1–6. 24 Hunter JA, Finkbeiner WE, Nadel JA, Goetzl EJ, Holtzman MJ. Predominant generation of 15-lipoxygenase metabolites of arachidonic acid by epithelial cells from human trachea. Clin Res 1985; 33: 78(abstr). 25 Ihle JN, Keller J, Oroszlan S, Henderson LE, Copeland TD, Fitch F, et al., Biologic properties of homogenous interleukin 3. J Immunol 1983; 131: 282–7. 26 Platzer E, Gramatzki M, Rollinghoff M, Kalden JR. Lymphokines and monokines in the clinic. Immunology Today 1987; 7: 185–7. 27 Otsuka H, Dolovich J, Bienenstock J, Denburg JA. Basophil/mast cell progenitors and growth factors in human nasal mucosa. J Allergy Clin Immunol 1986; 77: 247. 28 Burrow A, Eccles R, Jones AS. The effects of camphor, eucalyptus and menthol vapour on nasal resistance to airflow and nasal sensation. Acta Otolaryngol (Stockh) 1983; 96: 156–61. 29 Connell JT, Linzmayer I. Studies of rebound phenomena and oxymetazoline. J Allergy Clin Immunol 1988; 81: 179. 30 Angaard A, Malm L. Orally administered decongestant drugs in disorders of the upper respiratory passages: a survey of clinical results. Clin Otolaryngol 1984; 9: 43–9. 31 Richerson HB, Seebohm PH. Nasal airway response to exercise. J Allergy 1968; 41: 269–84. 32 Spector SL, Toshener D, Gray I, Rosenmann E. Beneficial effects of propylene and polyethylene glycol and saline in the treatment of perennial rhinitis. Clin Allergy 1982; 12: 187–96. 33 Druce HM, Bonner RF, Patow C, Choa P, Summers R, Kaliner MA. Response of nasal blood flow to neurohormone as measured by Laser-Doppler velocimetry. J Appl Physiol Respir Environ Exercise Physiol 1984; 57: 1276–84. 34 Howarth PH, Holgate ST. Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole for hay fever. Thorax 1984; 39: 668–72. 35 Corrado OJ, Oilier S, Phillips MJ, Thomas JM, Davies RJ. Histamine and allergen induced changes in nasal airways resistance measured by anterior rhinomanometry: reproducibility of the technique and the effect of topically administered antihistaminic and anti-allergic drugs. Br J Clin Pharmac 1987; 24: 283–92. 36 Rokenes HK, Andersson B, Rundcrantz H. Effect of terfenadine and placebo on symptoms after nasal allergen provocation. Clin Allergy 1988; 18: 63–9. 37 Sharpe MJ, Shapiro GG, Furukawa CT, Pierson WE, Bierman CW. Effect of chlorpheniramine (C) vs placebo (P) on nose and ear function of atopic subjects before and after histamine nasal challenge. J Allergy Clin Immunol 1988; 88: 175. 38 Meador K, Loring DW. Differential cognitive effects of terfenadine and chlorpheniramine. J Allergy Clin Immunol 1988; 88: 177. 39 Berman B, Buchman E, Dockhorn R, Leese P, Mansmann H, Middleton E. Cetirizine (C) therapy of perennial allergic rhinitis (PAR). J Allergy Clin Immunol 1988; 88: 177. 40 Kagey-Sobokta A, Norman PS, Lichtenstein LM. Effects of cetirizine on mast cell mediator release and cellular traffic during the cutaneous late response. J Allergy Clin Immunol 1988; 88: 212. 41 Scher C, Kirkegaard J, Borum P, Maansson A, Osterhammel P, Mygind N. Significance of H1 and H2 receptors in the human nose: rationale for topical use of combined antihistamine preparations. J Allergy Clin Immunol 1982; 70: 211–18. 42 Handelman NI, Friday GA, Schwartz HJ. Cromolyn sodium nasal solution in the prophylactic treatment of pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 1977; 59: 237–42. 43 Cohan RH, Bloom FL, Rhoades RB, Wiltig HJ, Haugh LD. Treatment of perennial rhinitis with cromolyn sodium. J Allergy Clin Immunol 1976; 58: 121–8. 44 Orgel HA, Meltzer EO, Kemp JP, Ostrom NK, Welch MJ. Comparison of intranasal cromolyn sodium and oral terfenadine for allergic rhinitis. J Allergy Clin Immunol 1988; 88: 256. 45 Corrado OJ, Gomez E, Baldwin DL, Clague JE, Davies RJ. The effect of nedocromil sodium on nasal provocation with allergen. J Allergy Clin Immunol 1987; 80: 218–22. 46 Sipila P, Sorn M, Pukander J. Double-blind placebo comparison of nedocromil sodium (1% nasal spray) and placebo in rhinitis caused by birch pollen. Clin Otolaryngol 1987; 12: 365–70. 47 Kirkegaard J, Mygind N, Molgard F, Grahne B, Holopaine E, Malmberg H, Brondbo K, Rojne T. Ordinary and high-dose ipratropium in perennial non-allergic rhinitis. J Allergy Clin Immunol 1987; 79: 585–90. 48 Brompton Hospital/Medical Research Council collaborative trial. Double-blind trial of two dosage schedules of beclomethasone dipropionate in the treatment of perennial rhinitis for twelve months. Clin Allergy 1980; 10: 239–51. 49 Munch E, Gomez G, Harris C, Lack RP, Edwards VA, O'Connor P, Snowden DV, Mygind N. An open comparison of dosage frequencies of beclomethasone dipropionate in seasonal allergic rhinitis. Clin Allergy 1981; 11: 303–9. 50 Siegel SC, Katz R, Rachelefsky GS, Geller BD, Mantag LL, Brandon ML, Cannon SJ. Multicentre study of beclomethasone dipropionate nasal aerosol in adults with seasonal allergic rhinitis. J Allergy Clin Immunol 1982; 69: 345–53. 51 Pipkorn U, Rundkrantz H. Budesonide and beclomethasone dipropionate in hay fever—a single blind comparison. Eur J Respir Dis 1982; 63(suppl 122): 22–30. 52 Hillas J, Booth RJ, Somerfield S, Morton R, Avery A, Wilson D. A comparative trial of intra-nasal beclomethasone dipropionate and sodium cromoglycate in patients with chronic perennial rhinitis. Clin Allergy 1980; 10: 253–8. 53 Tandon MK, Stranon EG. Double-blind crossover trial comparing beclomethasone dipropionate and sodium cromoglycate. Clin Allergy 1980; 10: 459–62. 54 Munch EP, Soborg M, Norreslet TT, Mygind N. A comparative study of dexchlorpheniramine maleate sustained release tablets and budesonide nasal spray in seasonal allergic rhinitis. Allergy 1983; 38: 517–24. 55 Wood SF. Oral antihistamine or nasal steroid in hay fever: a double-blind double-dummy comparative study of once daily oral astemizole vs. twice daily nasal beclomethasone dipropionate. Clin Allergy 1986; 16: 195–201. 56 Mygind N. Topical corticosteroid treatment for allergic rhinitis and allied conditions. Clin Otolaryngol 1982; 7: 343–53. 57 Klemi PJ, Virolainen E, Pubakka H. The effect of intranasal beclomethasone dipropionate on the nasal mucosa. Rhinology 1980; 18: 19–24. 58 Sahay JN, Ibrahim NBN, Chatterjee SS, Nassar WY, Lodge KV, Jones CW. Long-term study of flunisolide treatment in perennial rhinitis with special reference to nasal mucosal histology and morphology. Ann Allergy 1980; 10: 451–7. 59 Ganderton MA, James VHT. Clinical and endocrine side-effects of methylprednisolone acetate as used in hay fever. Br Med J 1970; 1: 267–9. 60 Borum P, Gronberg H, Brofeldt S, Mygind N. Effect of a depot injection of methylprednisolone in hay fever. In: N Mygind, B Weeke, eds. Allergic and vasomotor rhinitis—clinical aspects. Copenhagen : Munksgaard. 1985: 180–3. 61 Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Inhibition of mediator release in allergic rhinitis by pre-treatment with topical glucocorticosteroids. N Engl J Med 1987; 316: 1506–10. 62 Pipkorn U. Budesonide and nasal allergen challenge testing in man. Allergy 1982; 37: 129–34. 63 Okuda M, Sakaguchi K, Oktsuka H. Intranasal beclomethasone: mode of action in nasal allergy. Ann Allergy 1983; 50: 116–20. 64 Schleimer RP, Schulman ES, MacGlashan DW, Peters SP, Hayes EC, Adams GK, Lichtenstein LM, Adkinson NF. Effects of dexamethasone on mediator release from human lung fragments und purified human lung mast cells. J Clin Invest 1983; 71: 1830–5. 65 Robin JL, Seldin DC, Austen KF, Lewis RA. Regulation of mediator release from mouse bone marrow-derived mast cells by glucocorticosteroids. J Immunol 1985; 135: 2719–26. 66 Gomez E, Clague JE, Gatland D, Davies RJ. Effect of topical corticosteroids on seasonally induced increases in nasal mast cells. Br Med J 1988; 296: 1572–3. 67 Otsuka H, Denburg JA, Befus AD, Hitch D, Lapp P, Rajan RS, Bienenstock J, Dolovich J. Effect of beclomethasone dipropionate on nasal metachromatic cell sub-populations. Clin Allergy 1986; 16: 589–95. 68 Mygind N, Johnsen NJ, Thomsen J. Intranasal allergen challenge during corticosteroid treatment. Clin Allergy 1977; 7: 69–74. 69 Bascom R, Wachs M, Pipkorn U, Lichtenstein LM, Gallil SJ, Naclerio RM. Topical steroids block the influx of basophils Into the nose during the late response to nasal antigen challenge. Clin Res 1986; 625. 70 Schleimer RP. The mechanisms of anti-inflammatory steroid action in allergic diseases. Ann Rev Pharmacol Toxicol 1985; 25: 381–412. 71 Pauwels R. Review. Mode of action of corticosteroids in asthma and rhinitis. Clin Allergy 1986; 16: 281–8. 72 Wihl JA. Topical corticosteroids and nasal reactivity. Eur J Resp Dis 1982; 63(suppl 122): 205–10. 73 Malm L, Wihl JA, Lamm CJ, Lindquist N. Reduction of methacholine-induced nasal secretion by treatment with a new topical steroid in perennial non-allergic rhinitis. Allergy 1981; 36: 209–14. 74 Chatten R, Mackay I, Wilson R, Cole P. Double blind, placebo controlled trial of betamethasone nasal drops for nasal polyposis. Br Med J 1985; 291: 788. Citing Literature Volume19, Issue5September 1989Pages 559-568 ReferencesRelatedInformation